TRIUMPH/MyPathway analysis shows baseline circulating tumor DNA and prior anti-EGFR therapy affect pertuzumab plus trastuzumab efficacy in HER2-amplified metastatic colorectal cancer. (ESMO Open)
Baseline ctDNA profiling informs HER2-targeted therapy outcomes
The CRC Digest